PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children
Introduction Streptococcus pneumoniae is a causative agent of pneumonia and acute otitis
media (AOM), as well as invasive diseases such as meningitis and bacteremia. PCV15 …
media (AOM), as well as invasive diseases such as meningitis and bacteremia. PCV15 …
Phase 3 Safety and Immunogenicity Study of a Three-dose Series of Twenty-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers
P Korbal, J Wysocki, T Jackowska, M Kline… - The Pediatric …, 2024 - journals.lww.com
Background: Global pediatric immunization programs with pneumococcal conjugate
vaccines (PCVs) have reduced vaccine-type pneumococcal disease, but a substantial …
vaccines (PCVs) have reduced vaccine-type pneumococcal disease, but a substantial …
Immunogenicity of Current and Next-Generation Pneumococcal Conjugate Vaccines in Children: Current Challenges and Upcoming Opportunities
K Feemster, UK Buchwald, N Banniettis… - Open Forum …, 2024 - academic.oup.com
Global use of pneumococcal conjugate vaccines (PCVs) with increasingly broader serotype
coverage has helped to reduce the burden of pneumococcal disease in children and adults …
coverage has helped to reduce the burden of pneumococcal disease in children and adults …
A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+ 1 …
A Maestri, SE Park, F Fernandes, ZL Li… - Human Vaccines & …, 2024 - Taylor & Francis
There is an ongoing burden of pneumococcal disease in children despite the use of
pneumococcal conjugate vaccines (PCVs). This phase 3, open-label, single-arm, multisite …
pneumococcal conjugate vaccines (PCVs). This phase 3, open-label, single-arm, multisite …
[HTML][HTML] Respiratory Syncytial Virus (RSV): PCV13, PCV15 or PCV20: Which vaccine is best for children in terms of immunogenicity?
P De Wals - Canada Communicable Disease Report, 2024 - ncbi.nlm.nih.gov
Background The new 15-and 20-valent pneumococcal conjugate vaccines (PCV15 and
PCV20) have been marketed on the basis of immunogenicity criteria, one of them being a …
PCV20) have been marketed on the basis of immunogenicity criteria, one of them being a …